143248-63-9

Usage

InChI:InChI=1/C10H10N2O5/c13-10-8-3-1-2-4-9(8)16-7-11(10)5-6-17-12(14)15/h1-4H,5-7H2

Upstream product

• 119-36-8 methyl salicylate 
• 24207-38-3 N-(2-hydroxyethyl)salicylamide 
• 143248-39-9 3-(2'-acetoxyethyl)-2,3-dihydro-4H-1,3-benzoxazin-4-one 
• 143248-47-9 2,3-dihydro-3-(2'-hydroxyethyl)-4H-1,3-benzoxazin-4-one 
• 143248-55-9 3-(2-chloroethyl)-2H-1,3-benzoxazin-4(3H)-one 

Relevant academic research and scientific papers

Benzoxazinone and benzothiazinone derivatives having cardiovascular activity

Compounds of formula I STR1 wherein R represents hydrogen, C1 -C6 alkyl, C5 -C7 cycloalkyl, methylene-dioxy or phenyl, which may be substituted by one or two groups independently selected from hydroxy, halogen, nitro, C1 -C6 alkyl or C1 -C6 alkoxy; R1 and R2 independently represent hydrogen, COOR3, --CONR4 R5, STR2 --OCONR4 R5, --OCOR3, --NR4 R5, --OCOOR6, --NR3 COR7, --NRCONR4 R5, --N=CH--NR4 R5, NO2, CN, OH, SR3, wherein R3 is hydrogen or C1 -C6 alkyl, R4 and R5 independently are hydrogen or C1 -C6 alkyl, R6 is C1 -C6 alkyl, and R7 is hydrogen, C1 -C6 alkyl or C1 -C6 alkoxy, with the proviso that R1 and R2 cannot be hydrogen at the same time; X is oxygen or sulphur; Y represents a C2 -C6 alkylene chain or a C5 -C7 cycloalkylene group; and their pharmaceutically acceptable salts are provided and their use in pharmaceutical compositions which may be used in the treatment of cardiovascular diseases.

New Antianginal Nitro Esters with Reduced Hypotensive Activity. Synthesis and Pharmacological Evaluation of 3--2H-1,3-benzoxazin-4(3H)-ones

New nitro ester 3--2H-1,3-benzoxazin-4(3H)-ones show marked inhibitory activity against ischemia-induced electrocardiographic changes, with only limited systemic hemodynamic effects, and are reported in the present study.These new nitro vasodilators are potent inhibitors of the electrocardiographic T-wave and S-T segment elevation induced by intravenous or intracoronary administration of Arg-vasopressin or methacholine in the anesthetized rat.The most active compounds are up to 300- and 600- fold more potent than glyceryl trinitrate or Nicorandil, respectively.These nitro esters relax in a concentration-dependent manner the isolated rabbit aorta, at higher concentrations (2 - 40-fold) than glyceryl trinitrate, and reduce the mean arterial blood pressure at doses 7 - 300-fold higher than those required by glyceryl trinitrate to exert a similar hypotensive effect.Remarkably, these compounds retain their anti-ischemic and hemodynamic profile after oral (po) administration.These new nitro ester derivatives, endowed with a marked antianginal activity, which is not associated with concurrent and pronounced falls in systemic blood pressure, represent the leads of a new class of selective nitrovasodilators having a preferential action on large coronary vessels, which could be clinically relevant in the treatment of coronary artery diseases.

Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity

2,3-dihydro-4H-1,3-benzoxazin-4-ones and 2,3-dihydro-4H-1,3-benzothiaxin-4-ones of formula I wherein R represents hydrogen, (C1 6)alkyl, (C5 7)cycloalkyl, phenyl, phenyl substituted by hydroxy, halogen, nitro, (C1 6)alkyl, (C1 6)alkoxy, methylenedioxy; R1 and R2 independently represent hydrogen, amide, amino, carboxy, hydroxy, nitro, ciano, mercapto; X is an oxygen or sulphur atom; Y is a (C2 6)alkylene chain or (C2 6)cycloalkylene group; and the pharmaceutically acceptable acid or basic salts thereof.